Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial

析因分析 医学 达帕格列嗪 基线(sea) 内科学 事后 肾脏疾病 肾功能 糖尿病 内分泌学 2型糖尿病 生物 渔业
作者
Simke W. Waijer,Priya Vart,David Z.I. Cherney,Glenn M. Chertow,Niels Jongs,Anna Maria Langkilde,Johannes F.E. Mann,Ofri Mosenzon,John J.V. McMurray,Peter Rossing,Ricardo Correa‐Rotter,Bergur V. Stefánsson,Robert D. Toto,David C. Wheeler,Hiddo J.L. Heerspink
出处
期刊:Diabetologia [Springer Science+Business Media]
卷期号:65 (7): 1085-1097 被引量:68
标识
DOI:10.1007/s00125-022-05694-6
摘要

AIMS/HYPOTHESIS: In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial, dapagliflozin reduced the risks of progressive kidney disease, hospitalised heart failure or cardiovascular death, and death from all causes in patients with chronic kidney disease (CKD) with or without type 2 diabetes. Patients with more severe CKD are at higher risk of kidney failure, cardiovascular events and all-cause mortality. In this post hoc analysis, we assessed the efficacy and safety of dapagliflozin according to baseline Kidney Disease Improving Global Outcomes (KDIGO) risk categories. METHODS: and urinary albumin/creatinine ratio (UACR) of ≥22.6 and <565.0 mg/mmol (200-5000 mg/g) to dapagliflozin 10 mg/day or placebo. The primary endpoint was a composite of ≥50% reduction in eGFR, end-stage kidney disease (ESKD), and death from a kidney or cardiovascular cause. Secondary endpoints included a kidney composite (≥50% reduction in eGFR, ESKD and death from a kidney cause), a cardiovascular composite (heart failure hospitalisation or cardiovascular death), and death from all causes. We used Cox proportional hazards regression analyses to assess relative and absolute effects of dapagliflozin across KDIGO risk categories. RESULTS: Of the 4304 participants in the DAPA-CKD study, 619 (14.4%) were moderately high risk, 1349 (31.3%) were high risk and 2336 (54.3%) were very high risk when categorised by KDIGO risk categories at baseline. Dapagliflozin reduced the hazard of the primary composite (HR 0.61; 95% CI 0.51, 0.72) and secondary endpoints consistently across KDIGO risk categories (all p for interaction >0.09). Absolute risk reductions for the primary outcome were also consistent irrespective of KDIGO risk category (p for interaction 0.26). Analysing patients with and without type 2 diabetes separately, the relative risk reduction with dapagliflozin in terms of the primary outcome was consistent across subgroups of KDIGO risk categories. The relative frequencies of adverse events and serious adverse events were also similar across KDIGO risk categories. CONCLUSION/INTERPRETATIONS: The consistent benefits of dapagliflozin on kidney and cardiovascular outcomes across KDIGO risk categories indicate that dapagliflozin is efficacious and safe across a wide spectrum of kidney disease severity. TRIAL REGISTRATION: ClinicalTrials.gov NCT03036150. FUNDING: The study was funded by AstraZeneca.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
白bai发布了新的文献求助10
2秒前
米块发布了新的文献求助10
2秒前
嘻嘻发布了新的文献求助10
2秒前
曹琳完成签到,获得积分10
2秒前
parrot发布了新的文献求助10
3秒前
6666的应助被小孩采纳,获得10
3秒前
better发布了新的文献求助10
3秒前
喜悦发布了新的文献求助10
3秒前
丸giao关注了科研通微信公众号
3秒前
3秒前
3秒前
小蘑菇的应助被huan采纳,获得10
4秒前
右耳77完成签到 ,获得积分10
4秒前
小垃圾完成签到,获得积分10
4秒前
4秒前
4秒前
5秒前
卢不羁发布了新的文献求助10
5秒前
momo完成签到,获得积分10
5秒前
Ttanz完成签到,获得积分10
6秒前
水星冲浪的猫完成签到,获得积分10
6秒前
li发布了新的文献求助10
6秒前
鱼鱼鱼完成签到 ,获得积分10
7秒前
molihuakai的应助被tangz采纳,获得10
7秒前
苏苏驳回了今后的应助
7秒前
7秒前
DSL完成签到,获得积分10
8秒前
8秒前
呢呢发布了新的文献求助10
8秒前
8秒前
就不7香菜发布了新的文献求助10
8秒前
奋斗朋友发布了新的文献求助10
8秒前
甘幽独完成签到,获得积分10
8秒前
nancy发布了新的文献求助20
9秒前
TwistZz完成签到,获得积分10
9秒前
9秒前
慕青的应助被福宝采纳,获得10
9秒前
10秒前
追寻山河完成签到,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology)求助 1000
Encyclopedia of Modern Artificial Intelligence 1000
John McDowells Bildungstheorie 800
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Synthesis, Application and Future Perspectives of Smart Nano-materials - Part 1 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8153299
求助须知:如何正确求助?哪些是违规求助? 9549963
关于积分的说明 21695977
捐赠科研通 7741796
什么是DOI,文献DOI怎么找? 3425434
关于科研通互助平台的介绍 2550601
邀请新用户注册赠送积分活动 2469116